news
Lancet Review: Women on GLP-1s Lose Muscle, Face Access Issues
A new Lancet review highlights that women, who are the primary users of GLP-1s, are experiencing significant lean mass loss. Researchers noted current guidance isn't keeping up, leading to nutrient deficiencies and access barriers for this population. It's a call for better support and tailored protocols.
A new Lancet review highlights that women, who are the primary users of GLP-1s, are experiencing significant lean mass loss. Researchers noted current guidance isn't keeping up, leading to nutrient deficiencies and access barriers for this population. It's a call for better support and tailored protocols.
The architecture take
The conversation around GLP-1s usually fixates on the scale, but this Lancet review spotlights what's happening underneath all that fat loss: women are dropping muscle, and fast. I keep saying it, but weight loss isn't the same as health — especially if you're gutting your strength along with the fat. The problem isn't the drug itself, it's the lack of tailored nutritional and exercise protocols for women, who make up the majority of users. What's the point of reaching a 'healthy' BMI if you're weaker and have a higher risk of injury? This isn't just about nutrient gaps; it's about the systemic oversight in how these powerful metabolic tools are being prescribed and managed. Watch for more specialized clinics and programs to pop up, promising to mitigate muscle loss, because this isn't sustainable.